Clinical Trial Update: Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluated the efficacy of octreotide in patients with primary inoperable thymoma, sponsored by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymoma

Drugs mentioned

• Octreotide (Sandostatin) (Octreotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Thymoma | Phase 2 | Status: COMPLETED